Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sangamo Buys TxCell To Get In Early on CAR-Tregs In Immunology

Executive Summary

Sangamo is to pay €72m to acquire France's TxCell, a specialist in chimeric antigen receptor-modified regulatory T-cells. It hopes ultimately to apply its zinc finger nuclease gene editing technology to develop next-generation allogeneic CAR-Treg therapies for immunological conditions.

Advertisement

Related Content

J.P. Morgan 2019: Biopharma Sentiment Soars As Deal And Financing Optimism Abounds
Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal
Gilead May Have Better Takeover Targets Than Tesaro
Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
TxCell Plans First In Man Trial Of Regulatory T-Cells

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel